- Home
- CELC vs AVNT Comparison
CELC vs AVNT Comparison
Compare CELC & AVNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | AVNT |
|---|---|---|
| Founded | 2011 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CELC | AVNT |
|---|---|---|
| Price | $123.65 | $37.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $107.88 | $41.50 |
| AVG Volume (30 Days) | 633.0K | ★ 718.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.97% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.89 |
| Revenue | N/A | ★ $3,835,500,000.00 |
| Revenue This Year | N/A | $4.90 |
| Revenue Next Year | $740.70 | $3.48 |
| P/E Ratio | ★ N/A | $41.62 |
| Revenue Growth | N/A | ★ 1.71 |
| 52 Week Low | $8.54 | $27.48 |
| 52 Week High | $120.32 | $44.85 |
Technical Indicators
Market Signals| Indicator | CELC | AVNT |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 57.21 |
| Support Level | $99.38 | $35.07 |
| Resistance Level | N/A | $38.10 |
| Average True Range (ATR) | 6.14 | 1.11 |
| MACD | 1.10 | 0.38 |
| Stochastic Oscillator | 98.49 | 98.07 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.